Navigation Links
FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation
Date:10/19/2010

SILVER SPRING, Md., Oct. 19 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Pradaxa capsules (dabigatran etexilate) for the prevention of stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation).

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Atrial fibrillation, which affects more than 2 million Americans, involves very fast and uncoordinated contractions of the heart's two upper heart chambers (atria) and is one of the most common types of abnormal heart rhythm.

"People with atrial fibrillation are at a higher risk of developing blood clots, which can cause a disabling stroke if the clots travel to the brain," said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products in the FDA's Center for Drug Evaluation and Research.

Pradaxa is an anticoagulant that acts by inhibiting thrombin, an enzyme in the blood that is involved in blood clotting. The safety and efficacy of Pradaxa were studied in a clinical trial comparing Pradaxa with the anticoagulant warfarin. In the trial, patients taking Pradaxa had fewer strokes than those who took warfarin.

"Unlike warfarin, which requires patients to undergo periodic monitoring with blood tests, such monitoring is not necessary for Pradaxa," Stockbridge says.

As with other approved anti-clotting drugs, bleeding, including life-threatening and fatal bleeding, was among the most common adverse reactions reported by patients treated with Pradaxa. Gastrointestinal symptoms, including an uncomfortable feeling in the stomach (dyspepsia), stomach pain, nausea, heartburn, and bloating also were reported.

Pradaxa was approved with a Medication Guide that informs patients of the risk of serious bleeding. The guide will be distributed each time a patient fills a prescription for the medication.

Pradaxa, manufactured by Boehringer Ingelheim Pharmaceuticals Inc. of Ridgefield, Conn., will be available in 75 milligram and 150 milligram capsules.

For more information:

National Heart, Lung, and Blood Institute – What is Atrial Fibrillation?

http://www.nhlbi.nih.gov/health/dci/Diseases/af/af_what.html

Approved Drugs: Questions and Answers

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm

Media Inquiries: Sandy Walsh, 301-796-4669; sandy.walsh@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Botox to Treat Chronic Migraine
2. FDA Approves Injectable Drug to Treat Opioid-Dependent Patients
3. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
4. FDA Approves Combination Contraceptive Containing a Folate
5. U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels
6. FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters
7. FDA Approves New Dosing for FASLODEX® (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
8. FDA Approves Pediatric Use of Chemical Poisoning Treatment
9. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
10. FDA Approves Vaccines for the 2010-2011 Influenza Season
11. FDA Approves Strativa Pharmaceuticals Zuplenz® (ondansetron) Oral Soluble Film
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today ... programs. The hands-on learning experience is a 12-week summer ... Fellowship and Internship programs bring ... and interns are provided optional housing free of charge ... at the Riverfront Residence Hall to foster communication and ...
(Date:5/23/2016)... May 23, 2016 Non-invasive diagnostic ... of multiple diseases; ,Technology to be presented at Yissum’s ... Yissum Research Development Company of the Hebrew University of ... research agreement with Aurum Ventures MKI, the technology investment arm ... a new diagnostic approach for early detection of multiple ...
(Date:5/22/2016)... May 23, 2016 DS ... anti-fibrotic and anti-inflammatory compound DS102 in chronic obstructive ... non-alcoholic steatohepatitis (NASH) patients. Recent DS ... in lung tissue and has bronchodilatory, anti-inflammatory and ... administration. The Company will publish further detail on ...
Breaking Medicine Technology:
(Date:5/24/2016)... VA (PRWEB) , ... May 24, 2016 , ... Controlling ... smarter - with the launch of the Aquanta Water Heater Controller , a ... smart phone or web-enabled device. As the Nest thermostat does for HVAC systems, ...
(Date:5/24/2016)... WI (PRWEB) , ... May 24, 2016 , ... ... In Milwaukee , Out patient Services To Begin In June , Aloria Health, ... pleased to announce the opening of Aloria Milwaukee, its first treatment facility for ...
(Date:5/24/2016)... NJ (PRWEB) , ... May 24, 2016 , ... The ... that’s causing the problem. A common injury that’s often misunderstood, whiplash should be swiftly ... MD, a Harvard-trained, orthopedic spine surgeon at Atlantic Spine Center . , ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... successful implementation of protocols designed to reduce bleeding complications from percutaneous coronary intervention ... Angiography and Interventions (SCAI) in Orlando, FL, document a 40% reduction in risk-adjusted ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Essette Dashboard, its highly anticipated, web-based software module. The cutting-edge feature provides ... “secret sauce”? Integration with Izenda’s self-service business intelligence solution and its analytics ...
Breaking Medicine News(10 mins):